Alexander Mazein: Innovative Insights into Cytokine Release Syndrome via a Novel Explorable Model for Biotherapeutics and Cellular Therapies
Frontiers Immunology shared an innovative post from Alexander Mazein and researchers from Luxembourg Centre for System Biomedicine, University of Luxembourg, on X:
“New Research: An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies ”
Read the full article here:
Article: An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies
Authors: Alexander Mazein, Oxana Lopata, Kristin Reiche, Katherina Sewald, Miriam Alb, Christina Sakellariou, Patricia Gogesch, Hannah Morgan, Vanessa Neuhaus, Nhu-Nguyen Pham, Charline Sommer, Ethan Perkins, Birgit Fogal, Muhammad Shoaib, Reinhard Schneider, Venkata Satagopam, Marek Ostaszewski
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 18:14N. Mariana S. Vasquez: From Skin and Gut to Celiac Disease
-
Aug 26, 2026, 18:13Francesca Granata: What Happens When Patients Become Researchers and Researchers Become Advocates?
-
Aug 26, 2026, 18:11Maxima Mendez: Statins Are No Longer the Whole Story
-
Aug 26, 2026, 18:06Ashkan Shoamanesh: ANNEXa-I Analyses Inform Individualized Treatment in Intracranial Hemorrhage
-
Aug 26, 2026, 18:01Sam Tsimikas: Lp(a) and Oxidized Phospholipids Reveal a New Link Between Hypercoagulability and Stronger Clot Formation
-
Aug 26, 2026, 17:52Kamlesh Darji: A Practical Guide to Interpreting Coagulation Tests
-
Aug 26, 2026, 17:46Bruno Pougault: The Hidden Burden of Hemostatic Disorders in Women
-
Aug 26, 2026, 17:39Charan Gubba: Adult ITP – A major shift in the 2026 ASH Guidelines
-
Aug 26, 2026, 17:38Stephan A Mayer: Early Imaging Reveals Higher Risk of Hematoma Expansion After ICH